within Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BA04_Prednisolone;

model Prednisolone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.82,
    Cl = 2.1666666666666665e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.044,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.025,
    Tlag = 780,
    Vdp = 0.092,
    k12 = 2.0000000000000003e-06,
    k21 = 2.0000000000000003e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Prednisolone</td></tr><tr><td>ATC code:</td><td>S01BA04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>44</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Prednisolone is a synthetic glucocorticoid corticosteroid drug that exhibits anti-inflammatory and immunosuppressive properties. It is primarily used for the treatment of a wide range of inflammatory and autoimmune diseases, such as asthma, rheumatoid arthritis, and allergic reactions, as well as certain eye conditions. Prednisolone is approved for use today in various formulations, including ophthalmic preparations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data reported in healthy adult subjects after a single oral administration.</p><h4>References</h4><ol><li><p>de Truchis, C, et al., &amp; Boyer, O (2023). Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant. <i>British journal of clinical pharmacology</i> 89(5) 1532–1540. DOI:<a href=\"https://doi.org/10.1111/bcp.15610\">10.1111/bcp.15610</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36510685/\">https://pubmed.ncbi.nlm.nih.gov/36510685</a></p></li><li><p>Petersen, KB, et al., &amp; Schmiegelow, K (2003). Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. <i>Cancer chemotherapy and pharmacology</i> 51(6) 465–473. DOI:<a href=\"https://doi.org/10.1007/s00280-003-0602-3\">10.1007/s00280-003-0602-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12698270/\">https://pubmed.ncbi.nlm.nih.gov/12698270</a></p></li><li><p>Yoshida, K, et al., &amp; Chanu, P (2021). Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. <i>Journal of clinical pharmacology</i> 61(12) 1579–1591. DOI:<a href=\"https://doi.org/10.1002/jcph.1942\">10.1002/jcph.1942</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34273118/\">https://pubmed.ncbi.nlm.nih.gov/34273118</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01BA04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Prednisolone;
